立体定向再照射治疗SABR后野内复发肺癌:系统综述与荟萃分析
该系统综述与荟萃分析纳入12项研究197例患者,评估重复SABR挽救治疗野内复发肺癌的安全性与疗效。汇总1年和2年局部控制率分别为78.2%和68.0%,中位总生存26.3个月,≥2级肺炎发生率为6.4%。累积BED≥200 Gy组局部控制率显著高于低BED组(84.9% vs 64.9%,p=0.02)。
要点
- 重复SABR挽救治疗野内复发肺癌汇总1年局部控制率78.2%,2年68.0%。
- 累积BED≥200 Gy组局部控制率84.9% vs 低BED组64.9%(p=0.02)。
- ≥2级肺炎汇总发生率6.4%,≥3级毒性仅0.10%。
核心结论
- SABR野内再照射挽救治疗可获得高局部控制率和低毒性,尤其在累积BED≥200 Gy及间隔≥12个月的患者中。
- 重复SABR可能是经过选择患者的可行挽救选择,仍需前瞻性研究优化剂量与患者选择。
研究设计与样本
- 遵循PRISMA指南系统检索PubMed、Cochrane Library、MEDLINE和EMBASE数据库。
- 纳入标准为成年患者因肺癌SABR后野内复发(复发位于原PTV内)接受挽救性SABR治疗的研究。
- 排除野内失败距离PTV>1 cm或使用非SABR技术的研究。
- 共纳入12项研究197例患者进行定量分析,所有患者接受两程SABR,中位总剂量50 Gy分5次。
- 采用随机效应模型计算汇总1年和2年局部控制率、总生存及毒性,并用人群加权线性回归评估剂量学与临床病理变量和结局的关系。
主要发现
- 汇总1年局部控制率为78.2%(95%CI:66-87%),2年局部控制率为68.0%(95%CI:55-79%)。
- 累积BED≥200 Gy组局部控制率84.9%(95%CI:70-93%)vs 低BED组64.9%(95%CI:54-75%),p=0.02。
- 低BED组与高BED组中位总生存无显著差异(21.4 vs 32.6个月),但高BED组有生存改善趋势。
- 所有研究汇总中位总生存为26.3个月(95%CI:25.4-27.1)。
- 较小肿瘤(<2 cm)、初治更高BED及初治与再照射间隔较长(>12个月)与局部控制率改善相关(p<0.01)。
关键数值与推荐
- 累积BED≥200 Gy组局部控制率84.9%(95%CI:70-93%)vs 低BED组64.9%(95%CI:54-75%),p=0.02。
- 汇总≥2级肺炎发生率为6.4%,≥3级毒性报告率为0.10%。
- 所有研究中位总生存26.3个月(95%CI:25.4-27.1);低BED组21.4个月 vs 高BED组32.6个月,无显著差异。
- 肿瘤<2 cm、初治更高BED及间隔>12个月与局部控制率改善相关(p<0.01)。
临床怎么用
- 重复SABR可作为经过选择的SABR后野内复发肺癌患者的挽救治疗选项。
- 累积BED≥200 Gy与局部控制率改善相关,但需前瞻性研究优化剂量。
- 初治与再照射间隔>12个月及肿瘤<2 cm与局部控制率改善相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is paucity of data for thoracic in-field reirradiation with two courses of stereotactic ablative radiotherapy (SABR). This meta-analysis evaluates the safety and efficacy of repeat SABR as salvage therapy for in-field failures after definitive SABR. MATERIALS AND METHODS: A systematic search of PubMed, Cochrane Library, MEDLINE, and EMBASE databases was conducted in accordance with PRISMA guidelines. Studies were included if they involved adult patients treated with salvage SABR for in-field recurrences of lung cancer following prior SABR. To address varying definitions of local failure, studies were included if recurrence occurred within the original planning target volume (PTV). Studies with out-of-field failures (>1 cm from PTV) or those using non-SABR techniques were excluded. Pooled 1- and 2-year local control (LC) rates, overall survival (OS), and toxicities were calculated using a random-effects model. Population-weighted linear regression was employed to assess the relationship between dosimetric and clinico-pathologic variables and patient outcomes. RESULTS: Twelve studies involving 197 patients were included in the quantitative analysis. All patients received two courses of SABR, with a median total dose of 50 Gy in 5 fractions. Pooled 1- and 2-year LC rates were 78.2 % (95 % CI: 66-87 %) and 68.0 % (95 % CI: 55-79 %), respectively. Patients receiving a cumulative biologically effective dose (BED) ≥ 200 Gy had significantly higher LC rates (84.9 %, 95 % CI: 70-93 %) vs (64.9 %, 95 % CI: 54-75 %, p = 0.02). Median OS did not significantly differ between low and high BED groups, though there was a trend toward improved survival with higher BED (21.4 vs 32.6 months). The pooled median OS across all studies was 26.3 months (95 % CI: 25.4-27.1). Improved LC rates were associated with smaller tumours (<2 cm), higher BED from the initial treatment and longer interval (>12 months) between initial and repeat SABR (p < 0.01). Toxicities were minimal, with a pooled incidence of ≥ grade 2 pneumonitis at 6.4 % and only 0.10 % reporting ≥ grade 3 toxicity. CONCLUSIONS: Salvage in-field reirradiation with SABR achieves high local control and low toxicity, particularly in patients receiving higher cumulative BED (≥200 Gy) and with longer intervals (≥12 months) between treatments. These results suggest that repeat SABR is a viable salvage option for selected patients. Further prospective studies are needed to optimise dosing and patient selection for safe and effective reirradiation.
引用
- Jang K, Cross S, Yeghiaian-Alvandi R, et al. Stereotactic reirradiation for in-field lung cancer recurrence after stereotactic ablative radiotherapy: A systematic review and meta-analysis. Radiother Oncol. 2025. PMID: 40262688. doi:10.1016/j.radonc.2025.110898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。